ABIOMED, Inc. (NASDAQ:ABMD) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other brokerages have also commented on ABMD. Morgan Stanley restated an “equal weight” rating and issued a $140.00 price objective (up from $135.00) on shares of ABIOMED in a report on Monday, July 10th. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Jefferies Group LLC raised their price objective on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Piper Jaffray Companies set a $145.00 price objective on shares of ABIOMED in a report on Tuesday, July 4th. Finally, William Blair restated an “outperform” rating on shares of ABIOMED in a report on Thursday, June 8th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. ABIOMED currently has a consensus rating of “Buy” and a consensus price target of $158.29.

ABIOMED (NASDAQ:ABMD) opened at 147.67 on Friday. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of 86.36 and a beta of 0.20. ABIOMED has a 1-year low of $95.14 and a 1-year high of $157.41. The firm has a 50-day moving average price of $148.41 and a 200 day moving average price of $133.94.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.03. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business had revenue of $132.47 million during the quarter, compared to analyst estimates of $130.83 million. During the same period last year, the business posted $0.29 earnings per share. ABIOMED’s quarterly revenue was up 28.6% compared to the same quarter last year. Equities analysts predict that ABIOMED will post $2.24 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “ABIOMED, Inc. (ABMD) Stock Rating Lowered by BidaskClub” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/28/abiomed-inc-abmd-stock-rating-lowered-by-bidaskclub.html.

In other news, COO David M. Weber sold 16,500 shares of ABIOMED stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the completion of the transaction, the chief operating officer now directly owns 125,122 shares in the company, valued at $18,471,760.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Thomas sold 10,000 shares of ABIOMED stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the transaction, the director now owns 12,172 shares of the company’s stock, valued at $1,883,130.12. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in ABMD. Huntington National Bank acquired a new position in ABIOMED during the second quarter valued at about $100,000. Seven Eight Capital LP acquired a new position in ABIOMED during the second quarter valued at about $100,000. Creative Planning raised its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 129 shares during the last quarter. Virginia Retirement Systems ET AL acquired a new position in ABIOMED during the first quarter valued at about $200,000. Finally, Palladium Partners LLC acquired a new position in ABIOMED during the first quarter valued at about $211,000. Hedge funds and other institutional investors own 89.84% of the company’s stock.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.